

## NPPPharm Launches NPTab Technology

In the pharmaceutical industry, drug homogeneity has become more important in recent years as the efficiency of actives has increased and their concentrations in solid unit forms have decreased. Within the European, Japanese, and United States Pharmacopoeias' harmonization context, the requirements concerning the uniformity of dosage unit become increasingly stringent and difficult, using conventional formulation technology, to meet.

NPPPharm, subsidiary of the Ethypharm group, has answered the essential need for improved content uniformity of low-dosage drug in oral solid dosage forms with an innovative drug delivery system: the newly patented NPTab technology, a family of high functionality excipients, covered by a European granted patent (EP 1 200 071).

The content uniformity of solid low-dosage forms is a major challenge in the pharmaceutical

industry. This uniformity depends on the quality of both the initial mixture and the intermediate grain. The goal is thus to obtain the best dispersion of active within the excipients at every process level. Moreover, with a growing interest toward direct compression processes for solid dosage forms,

guaranteed homogeneity and reproducibility, allowing freedom from the problems involved in the stages of mixtures and the segregation phenomena.

The process comprises two steps. A layering process, spraying a drug solution onto a carrier, consisting of sugar spheres (homo-

the granular bed, compression parameters showed great reproducibility in tablet weight and hardness. Hardness levels, consistent with industrial production requirements, are obtained with intermediate pressures. NPTab is a high-functionality excipient that provides excellent flowability, high compressibility and compactibility, and guarantees drug content uniformity.

**NPPPharm has ... an innovative drug delivery system: the newly patented NPTab technology, a family of high functionality excipients, covered by a European granted patent.**

A new line of high functionality excipients has evolved from NPTab technology: NPTab classic, NPTab SR (Sustained Release), and NPTab QD (Quick Dissolve). NPTab technology enables the

pharmaceutical industry to develop cost-effective direct compression formulas of low dosage drugs with excellent content uniformity, a simplified process with a high level of confidence in terms of reproducibility and homogeneity. (www.nppharm.com - info@nppharm.fr)

neous particle size and texture), is followed by direct compression of the homogeneous layered sugar spheres. The layering uniformity guarantees a homogeneous distribution of drug. Furthermore, as a consequence of free-flowing properties of the layered sugar spheres and low stress heterogeneity inside

there is an increasing need for novel excipients that provide good flowability and compactibility.

NPTab technology has been designed to allow a very low dosage of the active drug in a tablet form, obtained by a direct compression process, with

Visit NPPPharm at **Hall VI b, Stand 6210**. ✱